公开(公告)号：US20180170975A1

公开(公告)日：2018-06-21

申请号：US15815512

申请日：2017-11-16

Applicant: Infectious Disease Research Institute

Inventor： Steven G. REED ,  Rhea N. COLER ,  Gregory C. IRETON ,  Sylvie BERTHOLET

IPC: C07K14/35 ,  G01N33/68 ,  A61K39/04 ,  C07K14/285

CPC classification number: C07K14/35 ,  A61K39/04 ,  A61K2039/55561 ,  C07K14/285 ,  C07K2319/00 ,  G01N33/5695 ,  G01N33/68 ,  G01N2469/20 ,  Y02A50/41 ,  Y02A50/55

Abstract: The present invention relates to compositions and fusion proteins containing at least two Mycobacterium sp. antigens, and polynucleotides encoding such compositions and fusion proteins. The invention also relates to methods for their use in the treatment, prevention and/or diagnosis of tuberculosis infections.

公开(公告)号：US09950063B2

公开(公告)日：2018-04-24

申请号：US14581062

申请日：2014-12-23

Applicant: Infectious Disease Research Institute

Inventor： Steven G. Reed ,  Darrick Carter

IPC: A61K39/39 ,  A61K9/107 ,  A61K39/00 ,  A61K39/35 ,  A61K45/06 ,  A61K39/008 ,  A61K39/04 ,  A61K39/145

CPC classification number: A61K39/39 ,  A61K9/107 ,  A61K39/0011 ,  A61K39/008 ,  A61K39/04 ,  A61K39/145 ,  A61K39/35 ,  A61K45/06 ,  A61K2039/55511 ,  A61K2039/55572 ,  Y02A50/386 ,  Y02A50/388 ,  Y02A50/39 ,  Y02A50/396 ,  Y02A50/41 ,  Y02A50/491

Abstract: Compositions and methods, including vaccines and pharmaceutical compositions for inducing or enhancing an immune response are disclosed based on the discovery of useful immunological adjuvant properties in a synthetic, glucopyranosyl lipid adjuvant (GLA) that is provided in substantially homogeneous form. Chemically defined, synthetic GLA offers a consistent vaccine component from lot to lot without the fluctuations in contaminants or activity that compromise natural-product adjuvants. Also provided are vaccines and pharmaceutical compositions that include GLA and one or more of an antigen, a Toll-like receptor (TLR) agonist, a co-adjuvant and a carrier such as a pharmaceutical carrier.

公开(公告)号：US20180028649A1

公开(公告)日：2018-02-01

申请号：US15729512

申请日：2017-10-10

Applicant: Infectious Disease Research Institute

Inventor： Steven G. REED ,  Darrick CARTER

IPC: A61K39/39 ,  A61K9/107 ,  C07H15/04 ,  C07H15/12 ,  A61K31/665 ,  A61K39/04 ,  A61K39/00 ,  A61K39/275 ,  A61K39/245 ,  A61K39/235 ,  A61K39/21 ,  C07H15/20 ,  A61K31/7016

CPC classification number: A61K39/39 ,  A61K9/107 ,  A61K31/665 ,  A61K31/7016 ,  A61K39/00 ,  A61K39/04 ,  A61K39/21 ,  A61K39/235 ,  A61K39/245 ,  A61K39/275 ,  A61K2039/525 ,  A61K2039/55572 ,  A61K2039/57 ,  A61K2039/575 ,  C07H15/04 ,  C07H15/12 ,  C07H15/20

Abstract: Compounds, particularly, glucopyranosyl lipid adjuvant (GLA) compounds, having the following structure (I) are provided: or a pharmaceutically acceptable salt thereof, wherein L1. L2, L3, L4, L5, L6, L7, L8, L9, L10, Y1,Y2, Y3, Y4, R1, R2, R3 , R4, R5, R6, are as defined herein. Pharmaceutical compositions, vaccine compositions, and related methods for inducing or enhancing immune responses, are also provided.

公开(公告)号：US09822152B2

公开(公告)日：2017-11-21

申请号：US13791511

申请日：2013-03-08

Applicant: Infectious Disease Research Institute

Inventor： Steven G. Reed ,  Rhea N. Coler ,  Gregory C. Ireton

IPC: C07K14/35 ,  G01N33/68 ,  A61K39/04 ,  C07K14/285 ,  G01N33/569 ,  A61K39/00

CPC classification number: C07K14/35 ,  A61K39/04 ,  A61K2039/55561 ,  C07K14/285 ,  C07K2319/00 ,  G01N33/5695 ,  G01N33/68 ,  G01N2469/20 ,  Y02A50/41 ,  Y02A50/55

Abstract: The present invention relates to compositions and fusion proteins containing at least two Mycobacterium sp. antigens, and polynucleotides encoding such compositions and fusion proteins. The invention also relates to methods for their use in the treatment, prevention and/or diagnosis of tuberculosis infections.

公开(公告)号：US09814772B2

公开(公告)日：2017-11-14

申请号：US15285378

申请日：2016-10-04

Applicant: Infectious Disease Research Institute

Inventor： Steven G. Reed ,  Darrick Carter

IPC: A61K39/39 ,  A61K39/00 ,  A61K31/7016 ,  A61K39/04 ,  C07H15/12 ,  A61K39/21 ,  A61K39/235 ,  A61K39/245 ,  A61K39/275 ,  C07H15/20 ,  C07H15/04 ,  A61K9/107 ,  A61K31/665

CPC classification number: A61K39/39 ,  A61K9/107 ,  A61K31/665 ,  A61K31/7016 ,  A61K39/00 ,  A61K39/04 ,  A61K39/21 ,  A61K39/235 ,  A61K39/245 ,  A61K39/275 ,  A61K2039/525 ,  A61K2039/55572 ,  A61K2039/57 ,  A61K2039/575 ,  C07H15/04 ,  C07H15/12 ,  C07H15/20

Abstract: Compounds, particularly, glucopyranosyl lipid adjuvant (GLA) compounds, having the following structure (I) are provided: or a pharmaceutically acceptable salt thereof, wherein L1, L2, L3, L4, L5, L6, L7, L8, L9, L10, Y1, Y2, Y3, Y4, R1, R2, R3, R4, R5, R6, are as defined herein. Pharmaceutical compositions, vaccine compositions, and related methods for inducing or enhancing immune responses, are also provided.

公开(公告)号：US20160158329A1

公开(公告)日：2016-06-09

申请号：US14780494

申请日：2014-03-28

Applicant: INFECTIOUS DISEASE RESEARCH INSTITUTE

Inventor： Jeff GUDERIAN ,  Malcolm DUTHIE ,  Steven G. REED

IPC: A61K39/008 ,  G01N33/569

CPC classification number: A61K39/008 ,  A61K2039/55566 ,  C07K16/20 ,  C07K2319/00 ,  G01N33/56905 ,  G01N2469/20 ,  Y02A50/41

Abstract: Compositions and methods for preventing, treating and detecting leishmaniasis are disclosed. The compositions generally comprise polypeptides comprising one or more Leishmania antigens as well as polynucleotides encoding such polypeptides.

Abstract translation: 公开了用于预防，治疗和检测利什曼病的组合物和方法。 组合物通常包含包含一种或多种利什曼原虫抗原的多肽以及编码这种多肽的多核苷酸。

公开(公告)号：US09056913B2

公开(公告)日：2015-06-16

申请号：US13895574

申请日：2013-05-16

Applicant: GLAXOSMITHKLINE BIOLOGICALS SA ,  INFECTIOUS DISEASE RESEARCH INSTITUTE

Inventor： Rhea Coler ,  Yves Lobet ,  Steven Reed

IPC: A61K39/04 ,  A61K49/00 ,  A61K39/02 ,  C07K14/35 ,  A61K31/4409 ,  A61K31/496 ,  A61K39/00

CPC classification number: A61K39/04 ,  A61K31/4409 ,  A61K31/496 ,  A61K2039/523 ,  A61K2039/53 ,  A61K2039/55566 ,  A61K2039/55572 ,  A61K2039/55577 ,  A61K2039/575 ,  C07K14/35

Abstract: The present invention is directed to methods of preventing reactivation of active and latent M. tuberculosis infections by administering a pharmaceutical composition comprising a nucleic acid encoding a Mtb72f fusion protein, or a Mtb72f fusion protein or an immunogenic fragment thereof, for example together with an adjuvant. The Mtb72f nucleic acid or fusion protein can be administered with one or more chemotherapeutic agents effective against a M. tuberculosis infection. The methods also provide for shortening the time course of a chemotherapeutic regimen against a M. tuberculosis infection.

Abstract translation: 本发明涉及通过施用包含编码Mtb72f融合蛋白或Mtb72f融合蛋白或其免疫原性片段的核酸的药物组合物，例如与佐剂一起施用来防止活性和潜伏性结核分枝杆菌感染的再活化的方法 。 Mtb72f核酸或融合蛋白可以与一种或多种对结核分枝杆菌感染有效的化学治疗剂一起施用。 所述方法还提供了缩短化疗方案针对结核分枝杆菌感染的时间过程。

公开(公告)号：US20150072354A1

公开(公告)日：2015-03-12

申请号：US14485515

申请日：2014-09-12

Applicant: Infectious Disease Research Institute

Inventor： Yasuyuki GOTO ,  Steven G. Reed

IPC: G01N33/569

CPC classification number: G01N33/56905 ,  G01N33/5008 ,  G01N33/5023 ,  G01N33/5091 ,  G01N33/6854 ,  G01N2500/00

Abstract: Compounds and methods are provided for diagnosing, preventing, treating and detecting leishmaniasis infection and stimulating immune responses in patients are disclosed. The compounds disclosed are include polypeptides and fusion proteins that contain at least one immunogenic portion of one or more Leishmania antigens, or a variant thereof. Additionally, methods of screening a screening library for tandem repeat proteins that have immunogenic properties are disclosed. Vaccines and pharmaceutical compositions comprising polynucleotides, polypeptides, fusion proteins and variants thereof that may be used for the prevention and therapy of leishmaniasis, as well as for the detection of Leishmaniasis infection are described.

Abstract translation: 提供了用于诊断，预防，治疗和检测利什曼病感染和刺激患者免疫应答的化合物和方法。 所公开的化合物包括含有一种或多种利什曼原虫抗原或其变体的至少一种免疫原性部分的多肽和融合蛋白。 另外，公开了筛选具有免疫原性的串联重复蛋白的筛选文库的方法。 描述了可用于预防和治疗利什曼病以及利什曼病感染检测的包含多核苷酸，多肽，融合蛋白及其变体的疫苗和药物组合物。

公开(公告)号：US20140050776A1

公开(公告)日：2014-02-20

申请号：US13895574

申请日：2013-05-16

Applicant: INFECTIOUS DISEASE RESEARCH INSTITUTE ,  GLAXOSMITHKLINE BIOLOGICALS SA

Inventor： Rhea COLLER ,  Yves Lobet ,  Steven Reed

IPC: C07K14/35 ,  A61K31/4409 ,  A61K31/496 ,  A61K39/04

CPC classification number: A61K39/04 ,  A61K31/4409 ,  A61K31/496 ,  A61K2039/523 ,  A61K2039/53 ,  A61K2039/55566 ,  A61K2039/55572 ,  A61K2039/55577 ,  A61K2039/575 ,  C07K14/35

Abstract: The present invention is directed to methods of preventing reactivation of active and latent M. tuberculosis infections by administering a pharmaceutical composition comprising a nucleic acid encoding a Mtb72f fusion protein, or a Mtb72f fusion protein or an immunogenic fragment thereof, for example together with an adjuvant. The Mtb72f nucleic acid or fusion protein can be administered with one or more chemotherapeutic agents effective against a M. tuberculosis infection. The methods also provide for shortening the time course of a chemotherapeutic regimen against a M. tuberculosis infection.

Abstract translation: 本发明涉及通过施用包含编码Mtb72f融合蛋白或Mtb72f融合蛋白或其免疫原性片段的核酸的药物组合物，例如与佐剂一起施用来防止活性和潜伏性结核分枝杆菌感染的再活化的方法 。 Mtb72f核酸或融合蛋白可以与一种或多种对结核分枝杆菌感染有效的化学治疗剂一起施用。 所述方法还提供了缩短化疗方案针对结核分枝杆菌感染的时间过程。